CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...